Jun 29, 2022 / 12:30PM GMT
Operator
Good morning, and welcome to the Trevi Therapeutics Phase IIb/III PRISM Top Line Data Conference Call. (Operator Instructions) Please note, this event may be recorded.
I would now like to turn the conference over to Katie McManus, Communications Manager of Trevi Therapeutics. Please go ahead.
Katie McManus -
On behalf of Trevi Therapeutics, I want to thank you for joining us for the Trevi Therapeutics Phase IIb/III PRISM top line data conference call of Haduvio for the treatment of prurigo nodularis.
Various remarks that management makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent quarterly form on Form 10-Q for the quarter ended March 31, 2022.
In
Trevi Therapeutics Inc Haduvio PRISM Ph2b/3 Data Call Transcript
Jun 29, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers